Benevolent AI (XAMS:BAI) Cash-to-Debt : 7.68 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Benevolent AI Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Benevolent AI's cash to debt ratio for the quarter that ended in Dec. 2023 was 7.68.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Benevolent AI could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Benevolent AI's Cash-to-Debt or its related term are showing as below:

XAMS:BAI' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.61 Med: 7.97 Max: No Debt
Current: 7.68

During the past 6 years, Benevolent AI's highest Cash to Debt Ratio was No Debt. The lowest was 4.61. And the median was 7.97.

XAMS:BAI's Cash-to-Debt is ranked better than
52.36% of 1526 companies
in the Biotechnology industry
Industry Median: 6.315 vs XAMS:BAI: 7.68

Benevolent AI Cash-to-Debt Historical Data

The historical data trend for Benevolent AI's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Benevolent AI Cash-to-Debt Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

7.48

8.27

4.61

12.03

7.68

Benevolent AI Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial				4.61	19.90	12.03	9.58	7.68

Competitive Comparison of Benevolent AI's Cash-to-Debt

For the Biotechnology subindustry, Benevolent AI's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Cash-to-Debt falls into.

Benevolent AI Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Benevolent AI's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	42.341	/	(1.074	+	4.438)
	=	7.68

Benevolent AI's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	42.341	/	(1.074	+	4.438)
	=	7.68

Benevolent AI (XAMS:BAI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Benevolent AI Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (XAMS:BAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (XAMS:BAI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BAIVF:USA 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.

Benevolent AI (XAMS:BAI) Headlines

No Headlines